WHO-2019-nCoV-genomic_sequencing
N Engl J Med 2019;380:2429-39.DOI: 10.1056/NEJMoa1901113
interim Guidance 1 December 2020. Updated version
This document provides updated guidance on mask use in health care and community settings, and during home care for COVID-19 cases. It is intended for policy makers, public health and infection prevention and control professionals, health care manag...ers and health workers.
The Annex provides advice on how to manufacture non-medical masks. It is intended for those making non-medical masks at home and for mask manufacturers
more
Временные руководящие принципы 1 декабря 2020 года. Обновленная версия
В этом документе представлено обновленное руководство по использованию масок в медицинских ...чреждениях и в общественных местах, а также при уходе за больными КОВИД-19 на дому. Он предназначен для разработчиков политики, специалистов в области общественного здравоохранения и профилактики и контроля инфекций, менеджеров здравоохранения и медицинских работников.
Приложение содержит рекомендации по изготовлению немедицинских масок. Оно предназначено для тех, кто производит немедицинские маски на дому и для производителей масок.
more
Ce document fournit des conseils provisoires sur la prévention, l'identification et la gestion de l'infection des travailleurs de la santé dans le contexte de COVID-19. Il s'adresse aux services de santé au travail, aux services ou points focaux de prévention et de contrôle des infections, aux ...administrateurs des établissements de santé et aux autorités de santé publique, tant au niveau national qu'au niveau des établissements.
more
Interim guidance2 November 2020
This interim guidance, originally entitled “Harmonized health service capacity assessments in the context of the COVID-19 pandemic”, is an update to the earlier version published on 31 May 2020 as “Harmonized modules for health ... facility assessment modules in the context of the COVID-19 pandemic”. In this update, module content has been further refined and developed
more
A Resource Guide for Country Offices
Five years after a global commitment to Fast-Track the HIV response and end AIDS by 2030, the world is off track. A promise to build on the momentum created in the first decade of the twenty-first century by front-loading investment and accelerating HIV service provision has been fulfilled by too fe...w countries.
more
Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t...o sustained behaviour change and is essential in overcoming barriers to access to services or generating demand for such services.
more
revised version December 2020
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w...ith HIV who are being treated for tuberculosis.
New recommendations launched today outline key new actions that countries can take to improve the delivery of HIV testing, treatment and care services by providing greater options for differentiated approaches such as, supporting HIV treatment start in the community, ensuring that children are diagnosed and treated early, and that viral load treatment monitoring is more accessible, focused and triggers clinical action
more
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more